In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death.
In COVID-19 clinical update #87, Dr. Griffin reviews PCR cycle threshold and RNA copy number, rapid antigen tests, hospitalization rate after infection or vaccination, allergies and vaccination, community transmission and viral RNA load, early treatment with sotrovimab, meta-analysis of tocilizumab treatment, antibiotic overuse, and guidelines on the use of anticoagulation for thromboprophylaxis.
In this special live-streamed episode of TWiV, Dr. Daniel Griffin fields questions on SARS-CoV-2 and COVID-19 from listeners.
In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.
In COVID-19 clinical update #85, Dr. Griffin reviews cases and deaths by vaccination status, mRNA vaccine effectiveness in 12-18 year olds, standard and extended dosing of mRNA vaccines, immune responses after vaccination, Moderna booster dose approved, giving monoclonals at home, no benefit from colchicine, and IFN does not help remdesivir.
In COVID-19 clinical update #84, Dr. Griffin discusses childrens’ antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.
David Tuller returns to TWiV to revisit his work to expose the methodological and ethical problems with the PACE trial, and the post-acute sequelae to SARS-CoV-2 infection, also known as long COVID.
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
In COVID-19 clinical update #81, Daniel Griffin discusses vaccine boosters, vaccination during pregnancy, mRNA vaccine comparison, J&J vaccine booster, EUA expansion for Lilly monoclonals, remdesivir reduces risk of hospitalization, and anticoagulation regimens.
In COVID-19 clinical update #80, Daniel Griffin reviews infections in children, masking, testing to limit transmission, high barrier for monoclonal antibody escape, are boosters needed, use of steroids, grants for long COVID, and how the pandemic unfolds in Africa.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.